IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting
Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination…
Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination…
The Binemon team is pleased to announce its strategic partnership with Cronos Chain. Los Angeles,…
Internet City, Dubai–(Newsfile Corp. – April 8, 2022) – LBank Exchange, a global digital asset…
2021 – FOURTH QUARTER AND FISCAL YEAR RESULTS FOURTH QUARTER 2021 HIGHLIGHTS INVOICED SALES INCREASED…
An economic solution for large wounds treated in the out-patient care setting PHOENIX–(BUSINESS WIRE)–#SAWC–Kerecis®, the…
SAN JUAN, Puerto Rico–(BUSINESS WIRE)–First BanCorp (the “Corporation”) (NYSE: FBP), the bank holding company for…
Highlights Include Company’s Progress in the Following Areas: Advances in the Research, Development, and Manufacturing…
SANTA MONICA, Calif.–(BUSINESS WIRE)–BlackRock TCP Capital Corp. (NASDAQ: TCPC) announced today that it will report…
The partnership includes designation as the “Official Bank” of the first-ever United States Mint Negro…
OXFORD, England & VIENNA, Austria–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today shared details of its participation…
VERO BEACH, Fla.–(BUSINESS WIRE)–Orchid Island Capital, Inc. (NYSE:ORC) (“Orchid” or the “Company”), a real estate…
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a…
– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and…
The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed…
– First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as…
– Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – –…
Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and…
– Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse…
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented…
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…